Claims for Patent: 12,263,158

Summary for Patent: 12,263,158

Title:	Tizanidine liquid preparation and use thereof
Abstract:	A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, disodium EDTA and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.
Inventor(s):	Gang Chen, Gongzheng CHEN, Song Lin, Rashmi Rohit PRASADE, Ganesh Dattatray CHAVAN PATIL
Assignee:	Fidelity Biopharma Co
Application Number:	US17/918,130
Patent Claims:	1. A liquid oral pharmaceutical composition, comprising a) about 0.2-10 mg/mL of tizanidine hydrochloride; b) a chelating agent; c) water, and a pharmaceutically acceptable excipient, wherein pH of the liquid pharmaceutical composition is between 3.5 and 6.5. 2. The liquid oral pharmaceutical composition according to claim 1, wherein the chelating agent is EDTA. 3. The liquid oral pharmaceutical composition according to claim 2, wherein the pH value of the liquid pharmaceutical composition is adjusted by one or more pH buffering agents. 4. The liquid oral pharmaceutical composition according to claim 1, wherein the liquid preparation comprises solvent, and the solvent is water; or wherein the other pharmaceutical excipient is one or more of a pH adjusting agent, a preservative, a co-solvent, a thickening agent, an aromatic agent, a sweetening agent and a coloring agent. 5. The liquid oral pharmaceutical composition according to claim 1, wherein when the liquid oral pharmaceutical composition is hermetically stored under the condition of 40° C./75% RH for 0-3 months, the total impurity amount of its related substances is ≤0.2%; and/or when the liquid oral pharmaceutical composition is hermetically stored under the condition of 25° C./60% RH for 0-6 months, the total impurity amount of its related substances is ≤0.2%. 6. The liquid oral pharmaceutical composition according to claim 1, wherein under a post-prandial condition, the evaluation criteria for the bioavailability equivalence are: the upper limit of the one-sided 95% confidence interval for Cmax is ≤0; the 90% confidence interval for AUC0-t is between 80%-125%; the 90% confidence interval for AUC0-¥ is between 80%-125%. 7. The liquid oral pharmaceutical composition according to claim 1, wherein the mean value of Tmax of the liquid oral pharmaceutical composition under the post-prandial condition is smaller than the mean value of Tmax of the tizanidine tablets/capsules under the post-prandial condition. 8. The liquid oral pharmaceutical composition of claim 2, further comprising d) about 2-6 mM citric acid, e) about 0.5-3 mM sodium citrate. 9. The liquid oral pharmaceutical composition of claim 8, further comprising f) about 2-10 mM of sodium methylparaben; and g) about 0.2-1 mM of sodium propylparaben. 10. The liquid oral pharmaceutical composition of claim 9, further comprising h) about 0.5-5 mM of sucralose. 11. The liquid oral pharmaceutical composition of claim 1, wherein the chelating agent is disodium EDTA. 12. The liquid oral pharmaceutical composition of claim 1, wherein the liquid pharmaceutical composition has a formula selected from the group consisting of Formula I-Formula V: Formula I: tizanidine hydrochloride 0.46 mg/ml, hydroxypropyl cellulose 25 mg/mL, colloidal silicon dioxide 5 mg/mL, 70% sorbitol solution 0.15 g/mL, sodium methylparaben 1 mg/mL, sodium propylparaben 0.1 mg/mL, disodium EDTA 1 mg/mL, sucralose 0.5 mg/mL, citric acid 0.90 mg/mL, sodium citrate 0.40 mg/mL, with remainder being water and optionally flavoring agent; Formula II: tizanidine hydrochloride 0.46 mg/mL, 70% sorbitol solution 250 mg/mL, sodium methylparaben 1 mg/mL, sodium propylparaben 0.1 mg/mL, disodium EDTA 1 mg/mL, sucralose 0.5 mg/mL, citric acid 0.90 mg/mL, sodium citrate 0.35 mg/mL, with remainder being water and optionally flavoring agent; Formula III: tizanidine hydrochloride 0.46 mg/mL, hydroxypropyl cellulose 25 mg/mL, 70% sorbitol solution 150 mg/mL, sodium methylparaben 1 mg/mL, sodium propylparaben 0.1 mg/mL, disodium EDTA 1 mg/mL, sucralose 0.5 mg/mL, citric acid 0.90 mg/mL, sodium citrate 0.46 mg/mL, with remainder being water and optionally flavoring agent; Formula IV: tizanidine hydrochloride 0.46 mg/mL, sodium methylparaben 1 mg/mL, sodium propylparaben 0.1 mg/mL, disodium EDTA 1 mg/mL, sucralose 0.5 mg/mL, citric acid 0.83 mg/mL, sodium citrate 0.42 mg/mL, with remainder being water and optionally flavoring agent; and Formula V: tizanidine hydrochloride 0.46 mg/mL, hydroxypropyl cellulose 50 mg/mL, sodium benzoate 1 mg/mL, glycerin 150 mg/mL, 70% sorbitol solution 250 mg/mL, disodium EDTA 1 mg/mL, sucralose 0.5 mg/mL, with remainder being water and optionally flavoring agent. 13. A method of administering tizanidine to a subject in need thereof for muscle relaxation, comprising administering a liquid oral pharmaceutical composition orally to said subject, wherein the pharmaceutical composition comprises a) about 0.2-10 mg/mL of tizanidine hydrochloride; b) a chelating agent; c) water, and a pharmaceutically acceptable excipient, wherein pH of the liquid oral pharmaceutical composition is between 3.5 and 6.5. 14. The method of claim 13, wherein the liquid oral pharmaceutical composition is administered to the subject either before meal or after meal with same clinical effect. 15. The method of claim 13, wherein said liquid oral pharmaceutical composition causes less or fewer adverse effects in the subject as compared to side effects caused by solid tablets or capsules of tizanidine at the same dosage. 16. The method of claim 13, wherein the liquid oral pharmaceutical composition further comprises d) about 2-6 mM citric acid, and e) about 0.5-3 mM sodium citrate. 17. The method of claim 16, wherein the liquid oral pharmaceutical composition further comprises f) about 2-10 mM of sodium methylparaben; and g) about 0.2-1 mM of sodium propylparaben. 18. The method of claim 17, wherein the liquid oral pharmaceutical composition further comprises h) about 0.5-5 mM of sucralose. 19. The method of claim 15, wherein the adverse effect comprises at least one of headache, dizziness, sedation, nausea drowsiness, asthenia, vertigo, or combination thereof. 20. The method of claim 19, wherein the liquid oral pharmaceutical composition causes lower incidence rate of drowsiness when administered to the subject as compared to incidence rate of drowsiness caused by solid tablets or capsules of tizanidine at the same dosage. 21. The liquid oral pharmaceutical composition of claim 1, wherein the pH of the liquid pharmaceutical composition is between 3.5 and 6.1. 22. The method of claim 13, wherein the pH of the liquid pharmaceutical composition is between 3.5 and 6.1.